CARLSBAD, CA  -  FEBRUARY 12, 2020 - Amicrobe Inc. closed their fully-subscribed $2.5 million convertible debt offering.  Proceeds from the financing will be used to support Amicrobe’s growth efforts and progress the development of Amicrobe’s two lead product candidates, Amicidin-α Surgical Gel and Amicidin-β Solution. In addition, this capital will support company operations as Amicrobe undertakes its next equity financing.

​

​

​

​